An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing ...

At the American Association for Cancer Research meeting in Chicago today (April 16), researchers from Genentech presented data showing atezolizumab combined with an antibody that interferes with ...

with Immune-Onc supplying IO-108 and retaining worldwide rights to the antibody. Approved by the US Food and Drug Administration for HCC, the combination of atezolizumab and bevacizumab received ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard ... the 18 patients who received the standard regimen ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

and developability comparable to the commercial therapeutic antibody Atezolizumab. Additionally, antibodies designed for EGFR(S468R) displayed exceptional specificity, precisely distinguishing the ...